Cdk5 (Cyclin-Dependent Kinase 5)

Pathway Diagram

flowchart TD
    CDK5["CDK5"]
    style CDK5 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    NEURONAL_MIGRATION["NEURONAL MIGRATION"]
    CDK5 -->|"regulates"| NEURONAL_MIGRATION
    Als["Als"]
    CDK5 -->|"activates"| Als
    Alzheimer["Alzheimer"]
    CDK5 -->|"therapeutic target"| Alzheimer
    CDK5 -->|"expressed in"| Als
    BECN1["BECN1"]
    CDK5 -->|"inhibits"| BECN1
    Ms["Ms"]
    CDK5 -->|"interacts with"| Ms
    Neurodegeneration["Neurodegeneration"]
    CDK5 -->|"inhibits"| Neurodegeneration
    CDK5 -->|"activates"| Ms
    Hyperthyroidism["Hyperthyroidism"]
    Hyperthyroidism -->|"upregulates"| CDK5
    TAU["TAU"]
    TAU -->|"associated with"| CDK5
    style NEURONAL_MIGRATION fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Alzheimer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style BECN1 fill:#4a1a6b,stroke:#4fc3f7,color:#e0e0e0
    style Ms fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Neurodegeneration fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Hyperthyroidism fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style TAU fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0

Introduction

Cdk5 — Cyclin Dependent Kinase 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cdk5 (cdk5 is a proline-directed serine/threonine kinase that, despite its name, is primarily active in postmitotic neurons rather than in dividing cells. Unlike other CDK family members, Cdk5 is not activated by cyclins but instead requires binding to its neuron-specific activators p35 (CDK5R1) or p39 (CDK5R2) for kinase activity (Tsai et al., 1994). Under physiological conditions, Cdk5 is essential for brain development, neuronal migration, synaptic function, and neuronal survival. However, pathological conversion of p35 to p25 by calpain-mediated cleavage results in sustained Cdk5 hyperactivation, which drives tau-protein hyperphosphorylation, neuronal death, and neurodegeneration in ^{2(2001). Structure and substrate regulation of the human Cdk5/p25 complex. *Molecular Cell*, 8(3):657-6692001 · DOI 10.1016/S1097-2765(01Open reference}2(/diseases/alzheimers-disease), ^{2(2001). Structure and substrate regulation of the human Cdk5/p25 complex. *Molecular Cell*, 8(3):657-6692001 · DOI 10.1016/S1097-2765(01Open reference}3(/diseases/parkinsons-disease), als, and other conditions (Shah & Bhatt, 2022).

Cdk5 is now recognized as one of the most important kinases in neurodegeneration and a prime therapeutic target. Its dual nature — essential for neuronal health yet destructive when dysregulated — poses both challenges and opportunities for drug development.

Structure

Kinase Domain Architecture

Cdk5 is a 291-amino-acid protein (~33.3 kDa) with the canonical bilobal kinase fold:

• N-terminal lobe (small lobe): consists of a five-stranded antiparallel beta-sheet and a single alpha-helix (the PSTAIRE-equivalent helix, which in Cdk5 reads PSSALRE). Contains the ATP-binding pocket and the glycine-rich loop for nucleotide positioning.

• C-terminal lobe (large lobe): predominantly alpha-helical; contains the activation segment (T-loop), the catalytic loop with the conserved aspartate residue (Asp144), and substrate recognition elements.

• Hinge region: connects the two lobes and forms part of the ATP-binding cleft; important for inhibitor design.

Activation Mechanism

Unlike other CDKs, Cdk5 does not require T-loop phosphorylation for activation. Instead, binding of p35 or p39 to the PSSALRE helix induces a conformational change that opens the substrate-binding cleft and positions the catalytic residues for phosphotransfer. This unique activation mechanism explains why Cdk5 escapes the cell-cycle regulatory machinery that controls other CDKs (Tarricone et al., 2001).

The p35-to-p25 Conversion

p35 is a short-lived protein (half-life ~20 minutes) normally degraded by the ubiquitin-proteasome system, keeping Cdk5 activity tightly controlled. Under neurotoxic stress — including Amyloid-Beta exposure, oxidative stress, excitotoxicity, or ischemia — the calcium-activated protease calpain cleaves p35 into p10 (N-terminal, membrane-anchoring fragment) and p25 (C-terminal, Cdk5-binding fragment). p25 has a much longer half-life (~60 minutes), causing prolonged Cdk5 activation. Moreover, p25 lacks the N-terminal myristoylation signal that anchors p35 to membranes, so the Cdk5/p25 complex is mislocalized from the membrane to the cytoplasm and nucleus, where it accesses pathological substrates including tau-protein, leading to neurodegeneration (Patrick et al., 1999).

Normal Function

Neuronal Migration and Cortical Development

Cdk5 is essential for proper cortical lamination during embryonic development. Cdk5 knockout mice die at birth with severe cortical layering defects due to failed neuronal migration. Cdk5 phosphorylates multiple substrates required for the cytoskeletal reorganization underlying neuronal migration, including:

• Doublecortin (DCX): regulation of microtubule bundling during migration

• Ndel1/Lis1: coupling of centrosome-nucleus movement to the leading process

• FAK: focal adhesion dynamics for motility

• CRMP-2: growth cone guidance and axon specification

Synaptic Function and Plasticity

At mature synapses, Cdk5 modulates both presynaptic and postsynaptic functions:

• Presynaptic: phosphorylates synapsin I, Munc18, and dynamin I, regulating synaptic vesicle cycling and neurotransmitter release

• Postsynaptic: phosphorylates NR2A and NR2B subunits of nmda-receptor receptors, PSD-95, and DARPP-32, modulating long-term-potentiation

• LTP/LTD: Cdk5 activity is required for certain forms of long-term potentiation and long-term depression

Neuronal Survival

Physiological Cdk5/p35 activity promotes neuronal survival through:

• Phosphorylation and inactivation of pro-apoptotic proteins (e.g., p53 family members)

• Maintenance of cytoskeletal integrity via neurofilament phosphorylation

• DNA damage response signaling

• Cell cycle suppression in postmitotic neurons — loss of Cdk5 activity allows aberrant cell cycle re-entry, leading to neuronal death

Neurofilament Phosphorylation

Cdk5 directly phosphorylates the KSP repeats in nfl-protein medium (NEFM) and heavy (NEFH) chain tail domains. This phosphorylation increases neurofilament sidearm extension, regulating inter-filament spacing and thus axonal caliber. Cdk5-mediated neurofilament phosphorylation is a major determinant of axonal diameter and nerve conduction velocity.

Role in Disease

Alzheimer’s Disease

Cdk5/p25 hyperactivation is a central pathogenic mechanism in ^{2(2001). Structure and substrate regulation of the human Cdk5/p25 complex. *Molecular Cell*, 8(3):657-6692001 · DOI 10.1016/S1097-2765(01Open reference}4(/diseases/alzheimers-disease):

• tau-protein hyperphosphorylation]: Cdk5/p25 phosphorylates tau-protein at multiple disease-associated sites including Ser202, Thr205, Ser235, and Ser404. These phosphorylations reduce tau’s affinity for microtubules, promote its aggregation into neurofibrillary tangles, and correlate with braak-staging of AD (Patrick et al., 1999).

• Amyloid-Beta processing: Cdk5 can phosphorylate bace1-protein (https://www.ncbi.nlm.nih.gov/gene/930, increasing its activity and promoting amyloidogenic processing of app-protein.

• Neuronal cell cycle re-entry: Cdk5/p25 drives aberrant cell cycle activation in postmitotic neurons, a lethal event.

• DNA damage: Cdk5 hyperactivation in the nucleus causes widespread DNA damage and genomic instability, contributing to neuronal death (Kim et al., 2008).

Elevated p25/p35 ratios are found in brains of AD patients, and p25 levels correlate with disease severity and tau pathology (Cruz et al., 2006).

Parkinson’s Disease

In ^{2(2001). Structure and substrate regulation of the human Cdk5/p25 complex. *Molecular Cell*, 8(3):657-6692001 · DOI 10.1016/S1097-2765(01Open reference}5(/diseases/parkinsons-disease), Cdk5 contributes to dopaminergic-neurons-snpc degeneration through:

• Phosphorylation and modulation of parkin (parkin activity

• Phosphorylation of alpha-synuclein at Ser87

• Regulation of lrrk2-protein activity

• Promotion of oxidative-stress and mitochondrial-dysfunction via drp1 phosphorylation

ALS

In als, Cdk5/p25 activity is elevated in spinal cord motor neurons. Cdk5 hyperactivation contributes to:

• Hyperphosphorylation of neurofilaments, disrupting axonal transport

• Phosphorylation of sod1-protein mutants, modulating their toxicity

• Dysregulation of rna-metabolism in motor neurons

Frontotemporal Dementia

In ftd tauopathies, Cdk5/p25 inhibition attenuates tau pathology, neuroinflammation, and neuronal loss. Inhibition of the p25/Cdk5 complex in mouse and iPSC models of FTD reduces tau phosphorylation, neuroinflammation, DNA damage, and cell cycle re-entry (Seo et al., 2017).

Huntington’s Disease

Cdk5 phosphorylates huntingtin at Ser434, which may modulate huntingtin toxicity and aggregate formation in huntington-pathway.

Therapeutic Targeting

Small Molecule Inhibitors

• Roscovitine: a broad CDK inhibitor that attenuates Cdk5 hyperactivity and ameliorates p25-associated pathologies including DNA damage, tau phosphorylation, and neuronal death. However, its lack of selectivity for Cdk5 over other CDKs limits clinical utility.

• Dinaciclib: another CDK inhibitor with activity against Cdk5, used primarily in oncology but studied in neurodegeneration contexts.

Peptide-Based Approaches

A 12-amino-acid Cdk5-derived peptide (CIP) that specifically disrupts the Cdk5/p25 complex without affecting Cdk5/p35 activity represents a more targeted approach. This peptide selectively inhibits the pathological Cdk5/p25 interaction while preserving the physiological Cdk5/p35 function, ameliorating neurodegenerative phenotypes in cell and mouse models (Bhatt et al., 2023).

p35/p25 Modulation

Strategies to prevent p35-to-p25 conversion by inhibiting calpain activity or stabilizing p35 are under investigation. Calpain inhibitors reduce p25 generation and tau hyperphosphorylation in AD models.

Brain Atlas Resources

• Allen Human Brain Atlas: Cdk5 — Cyclin-Dependent Kinase 5 expression search

• Allen Mouse Brain Atlas: Cdk5 — Cyclin-Dependent Kinase 5 search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Cdk5 — Cyclin-Dependent Kinase 5 developmental expression

See Also

• neurons

• [Diseases Index

• [Entities Index

• [Mechanisms Index

External Links

• UniProt: Q00535

• PDB: 1UNL

• KEGG: cdk5 pathway

• UniProt: Q00535

• PDB: 1UNL

• KEGG: cdk5 pathway

• UniProt: Q00535

• PDB: 1UNL

• KEGG: cdk5 pathway

• PubMed - Literature database

• NCBI - National Center for Biotechnology Information

Background

The study of Cdk5 — Cyclin Dependent Kinase 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources